Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 40 clinical trials
Study of Lorlatinib in ROS1 Rearranged NSCLC

This is a phase II, multi-center, single arm study of lorlarinib as a single agent in patients with ROS1-rearranged advanced NSCLC.

measurable disease
cancer chemotherapy
recurrent non-small cell lung cancer
platinum doublet
kidney function test
  • 0 views
  • 25 Jan, 2021
  • 1 location
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

This phase II Pediatric MATCH trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back (recurrent) or do not respond to treatment (refractory) and have spread to other places in the body (advanced). …

bone marrow procedure
cancer
neutrophil count
interleukins
ensartinib
  • 68 views
  • 18 Feb, 2021
  • 74 locations
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2

This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with neurofibromatosis type 2 (NF2) with associated progressive tumors of vestibular schwannomas (VS), non-vestibular schwannomas (non-VS), meningiomas, and ependymomas. This Master Study is being conducted as a "basket" study that may allow …

measurable disease
nf2 gene
cataract
brigatinib
bilateral tubal ligation
  • 7 views
  • 26 Jan, 2021
  • 1 location
A Retrospective Pharmacogenomics Research of EGFR-TKIs Gefitinib and Erlotinib in NSCLC Patients Treatment

For patients of advanced NSCLC (non small cell lung cancer) , Individualized cancer therapy has been widely accepted since the success of crizotinib administration based on EML4-ALK fusion gene

erlotinib
gefitinib
lung carcinoma
crizotinib
EGFR
  • 4 views
  • 26 Jan, 2021
  • 1 location
Crizotinib in ALK Rearranged Non-small-cell Lung Cancer

This is a multicenter, observational, retrospective cohort study aimed at assessing the efficacy and safety of crizotinib in ALK positive NSCLC treated in real life setting.

lung cancer
cancer
lung carcinoma
crizotinib
metastasis
  • 0 views
  • 24 Jan, 2021
  • 21 locations
Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer

This study was designed to explore the efficacy and safety of Crizotinib as a first-line treatment for advanced NSCLC with ROS1 rearrangement positive mutation in the real world, explore the new

non-squamous non-small cell lung cancer
lung carcinoma
squamous non-small cell lung cancer
crizotinib
proto-oncogene tyrosine-protein kinase ros
  • 3 views
  • 24 Jan, 2021
  • 2 locations
Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer

This study aims to explore the efficacy and safety of Crizotinib as a first-line therapy for advanced non-squamous non-small cell lung cancer with ALK-positive mutations in the real world.

squamous non-small cell lung cancer
crizotinib
non-squamous non-small cell lung cancer
lung carcinoma
  • 6 views
  • 24 Jan, 2021
  • 2 locations
Clinical Pharmacokinetics of TKIs in Chinese Patients of Hepatitis B (HBV)

The study will explore the characteristics in clinical pharmacokinetics of gefitinib, erlotinib,afatinib,osimertinib, crizotinib, apatinib, icotinib in Chinese patients of Non-small-cell lung

icotinib
tyrosine
cancer
erlotinib
growth factor
  • 5 views
  • 22 Jan, 2021
  • 1 location
A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

The primary purpose of this study is to determine the differences in PFS for participants who have been receiving brigatinib as ALK inhibitor therapy for ALK+NSCLC compared to those participants receiving alectinib, ceritinib, lorlatinib, or other ALK inhibitors that may become available during study treatment.

brigatinib
alectinib
crizotinib
lung carcinoma
  • 15 views
  • 25 Jan, 2021
  • 1 location
Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy

This is a prospective trial for a computation-based efficacy prediction method for anticancer target therapies. The original computational algorithm utilizes individual transcriptome data of a cancer sample and assesses changes at the level of gene expression and intracellular signaling pathways. By applying the database of known molecular targets of anticancer …

primary cancer
  • 34 views
  • 22 Jan, 2021
  • 7 locations